1. What is the Chemxpert database?

Chemxpert database is a techno-commercial information platform developed and operated by Lifescience Intellipedia Pvt. Ltd. Our data provides valuable insights regarding sourcing, marketing, development, and regulatory functions for the entire Lifescience industry. The different industries covered by our data encompass APIs, FDFs, pharma intermediates, paints, dyes, polymers, biotechnology, biochemical, food additives, nutraceuticals, etc.

2. How can I subscribe to the Chemxpert database?

You can gain access to the Chemxpert database after subscribing to it by visiting this link: - https://chemxpert.com/pricing

3. How many countries' data is available on your portal?

The Chemxpert database covers more than 200 countries. We are working in the direction of expanding our data coverage in more countries.

4. What are the different sources you use for obtaining information?

The different sources we use for data collection are as follows: - • Primary researc • DMF, ANDA, & CEP list • Conferences, Exhibitions, & Tradeshow • Company annual reports • DMF, ANDA, & CEP list • Subject matter experts & KOL survey. Apart from these, our other valuable sources include application-wise manufacturers list, subscribed and non-subscribed databases, corporate partners, US FDA Orange book, publicly available sources, industry associates, national statistics, regulatory websites, etc. You can gain access to the Chemxpert database after subscribing to it by visiting this link: -https://chemxpert.com/sources

5. What is the expected time for account activation?

Your Chemxpert account will be activated instantly if the payment is made through our website. If you choose to use RTGS, NEFT, or IMPS systems for payment, your account will be activated within 24 hours.

06 Dec 2022
Admin
News Article

CCI approves Bharat Biotech International Eastman Exports deal

The deal has been approved under the green channel route, wherein a transaction which does not raise any risk of an appreciable adverse effect on competition is deemed to be approved on it being intimated to the competition watchdog. In a release on the CCI's website, the fair trade regulator said it has approved the deal. The Competition Commission of India on Monday said it has approved the proposed deal of Bharat Biotech International Ltd for acquiring shares of Eastman Exports Global Clothing Pvt Ltd through a share purchase agreement. The deal has been approved under the green channel route, wherein a transaction which does not raise any risk of an appreciable adverse effect on watchdog. In a release on the CCI's website, the fair trade regulator said it has approved the deal. The proposed combination relates to the acquisition of shares of Eastman Exports Global Clothing (EEGC) by Bharat Biotech International Ltd (BBIL) being implemented by way of the share subscription agreement, share purchase agreement. "Given that there are no horizontal overlaps, vertical and/or complementary links between the activities of the BBIL (including its affiliates) and EEGC, the proposed combination is being notified under the green channel route," CCI said. BBIL is engaged in the activity of manufacturing of human vaccines and biotherapeutics, while EEGC is engaged in the business of sourcing, buying, distribution and sales of yarn, fabric and apparels.

Let’s apply Data-Driven Pricing to Your APIs

Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.

Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.

Start using market intelligence today and allow yourself to be in control in the API market.

Check it out today and make more informed sourcing decisions! Learn More!